Vicadrostat

also known as BI 690517 · vica

Developed for: chronic kidney disease · heart failure · diabetic kidney disease · diastolic heart failure · hypertensive disorder · type 2 diabetes mellitus
Investigated by: Boehringer Ingelheim · Baim Institute for Clinical Research · DELPHINIUM · IQVIA global CRO · University Medical Center Groningen

Trials 20

today NCT07857772 · Ph 2 NCT07845630 · Ph 1 NCT07304817 · Ph 2 NCT07513207 · Ph 1 NCT07133399 · Ph 1 NCT07064473 · Ph 3 NCT06926660 · Ph 2 NCT07035457 · Ph 1 NCT06935370 · Ph 3 NCT06647810 · Ph 1 NCT06531824 · Ph 3 NCT06424288 · Ph 3 NCT05731908 · Ph 1 NCT05515588 · Ph 1 NCT05182840 · Ph 2 NCT03608072 · Ph 1 NCT03165240 · Ph 1 NCT03206632 · Ph 1 NCT03100916 · Ph 1 NCT02891148 · Ph 1

20172018201920202021202220232024202520262027202820292030

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 112 trials
Phase 1	NCT07845630	Oct → Dec 2026 expected	—	Boehringer Ingelheim	Not yet recruiting	No outcome recorded
Phase 1	NCT07513207	Apr → Jul 2026	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT07133399	Sep → Oct 2025	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT07035457	Jul → Aug 2025	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT06647810	Nov → Dec 2024	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT05731908	Feb → Apr 2023	liver disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT05515588	Sep → Nov 2022	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT03608072	Aug 2018 → Jan 2019	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT03165240	Oct 2017 → Apr 2020	diabetic kidney disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT03206632	Jul → Oct 2017	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT03100916	May → Nov 2017	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02891148	Sep → Dec 2016	—	Boehringer Ingelheim	Completed	No outcome recorded

Phase 24 trials
Phase 2	NCT07857772	Mar 2027 → May 2028 expected	diastolic heart failure	Baim Institute for Clinical Research	Not yet recruiting	No outcome recorded
Phase 2	NCT07304817	May 2026 → Feb 2028 expected	chronic kidney disease, heart failure	University Medical Center Groningen	Recruiting	No outcome recorded
Phase 2	NCT06926660	Jul 2025 → Aug 2026	chronic kidney disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT05182840	Jan 2022 → Jun 2023	chronic kidney disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 34 trials
Phase 3	NCT07064473	Jul 2025 → Dec 2029 expected	hypertensive disorder, type 2 diabetes mellitus	Boehringer Ingelheim	Recruiting	No outcome recorded
Phase 3	NCT06935370	May 2025 → Feb 2029 expected	heart failure	Boehringer Ingelheim	Recruiting	No outcome recorded
Phase 3	NCT06531824	Aug 2024 → Dec 2026 expected	chronic kidney disease	Boehringer Ingelheim	Active not recruiting	No outcome recorded
Phase 3	NCT06424288	Jun 2024 → May 2028 expected	heart failure	Boehringer Ingelheim	Recruiting	No outcome recorded

News releases announcing trial results or a regulatory action · 1

Date	Issuer	Release
2023-11-06	Boehringer Ingelheim	Results Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial prnewswire.com ↗ The results showed a significant reduction of albuminuria, a marker of kidney damage, 2 by up to 39.5% when BI 690517 was given on top of empagliflozin, a sodium glucose cotransporter (SGLT2) inhibitor, vs. placebo.

All press releases naming this drug 1 release

Date	Issuer	Release
2023-11-06	Boehringer Ingelheim	Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial prnewswire.com ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 22 sources stand behind the page.

Field	Value	Cited text
Known as	Vicadrostat	“vicadrostat in combination with empagliflozin” NCT07857772 ↗ 9 NCT07035457 ↗ NCT06926660 ↗ NCT06935370 ↗ NCT07304817 ↗ NCT06424288 ↗ NCT07133399 ↗ NCT07064473 ↗ NCT07513207 ↗ NCT07845630 ↗
Known as	BI 690517	“vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure.” NCT06424288 ↗ 11 “Oral Vicadrostat (BI 690517)” NCT06935370 ↗ NCT05515588 ↗ NCT03206632 ↗ NCT03608072 ↗ NCT03165240 ↗ NCT02891148 ↗ NCT05731908 ↗ NCT03100916 ↗ NCT06531824 ↗ NCT05182840 ↗ Show 1 more source
Known as	vica	“vicadrostat/empagliflozin (vica/empa)” NCT07857772 ↗
Action	Inhibit	“Aldosterone synthase inhibitor (BI 690517)” PMID 38497241 ↗ Mar 2024
Modality	Small molecule	— CHEMBL6068035 ↗
Route	Oral	“once-daily oral BI 690517 3, 10 or 40 mg” PMID 38497241 ↗ Mar 2024